Fundz
Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Percheron Therapeutics Limited Appoints Deborah Ambrosini As Chief Financial Officer and Company Secretary, Replacing Phillip Hains

PRIVATEJun 17, 2024•almost 2 years ago

Position

Company Secretary

Company

Percheron Therapeutics Limited

Deborah Ambrosini
research

Description

Percheron Therapeutics Limited announces the appointment of Deborah Ambrosini as the new Chief Financial Officer and Company Secretary, replacing Phillip Hains. Ambrosini's extensive experience in finance and the healthcare sector will support Percheron's expansion and investment initiatives.

Company Information

Company

Percheron Therapeutics Limited

Location

35 Collins St

About

Percheron Therapeutics Limited is an Australian biotechnology company focused on developing antisense pharmaceutical therapies for cancer and rare diseases. Formerly known as Antisense Therapeutics Limited, the company rebranded in 2024 and is publicly traded on the Australian Securities Exchange under the code ANP. Headquartered in Melbourne, Percheron operates with a dedicated team and emphasizes transparency in its operations and financial reporting. The company specializes in antisense pharmaceuticals, which target RNA to treat diseases at the genetic level. Its product pipeline includes ATL1102, currently in Phase IIb clinical trials for Duchenne Muscular Dystrophy, and ATL1103, which has been previously reported. Percheron aims to address significant unmet medical needs, particularly for patients with rare diseases and cancer, and has secured regulatory approvals for its trials in the UK and Turkey. With reported revenues of approximately AUD 2.97 million in 2024, Percheron is committed to delivering innovative therapies to underserved patient populations.

Predictive Intelligence
Strategic

ML-powered predictions for Percheron Therapeutics Limited's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.